---
title: "腾邦控股：清盘人共收到 2 份建议书 并正在商讨订立排他性协议"
description: "智通财经 APP 讯，腾邦控股发布公告，清盘人就公司债务重组及找寻 “白武士” 的可能性积极与多方接触，并与表示有意参与的各方进行讨论。截至本公告日期，清盘人共收到 2 份建议书，并正在商讨订立排他性协议。公司股份继续停牌。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/202340000.md"
published_at: "2024-04-19T08:36:03.000Z"
---

# 腾邦控股：清盘人共收到 2 份建议书 并正在商讨订立排他性协议

> 智通财经 APP 讯，腾邦控股发布公告，清盘人就公司债务重组及找寻 “白武士” 的可能性积极与多方接触，并与表示有意参与的各方进行讨论。截至本公告日期，清盘人共收到 2 份建议书，并正在商讨订立排他性协议。公司股份继续停牌。

智通财经 APP 讯，腾邦控股 (06880) 发布公告，清盘人就公司债务重组及找寻 “白武士” 的可能性积极与多方接触，并与表示有意参与的各方进行讨论。截至本公告日期，清盘人共收到 2 份建议书，并正在商讨订立排他性协议。

公司股份继续停牌。

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-CN/news/276113491.md) |
| Robosense Technology Forecasts Lower 2025 Losses | Robosense Technology Forecasts Lower 2025 Losses | [Link](https://longbridge.com/zh-CN/news/276402015.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| RoboSense Flags Sharply Narrowed 2025 Loss on Strong LiDAR Sales | RoboSense Technology Co., Ltd. (HK:2498) expects its net loss for 2025 to narrow to no more than RMB180 million, down fr | [Link](https://longbridge.com/zh-CN/news/276340976.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。